Abstract
Our group has previously demonstrated that oxidized phospholipids derived from mildly oxidized low density lipoprotein (MM-LDL) or oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (oxPAPC) increase monocyte-endothelial interactions. There are indications that the effects of these phospholipids are receptor mediated. Oxidized phospholipids have previously been shown to activate cells via the platelet activating factor (PAF) receptor, therefore, we pretreated human aortic endothelial cells (HAECs) with a PAF-receptor antagonist (WEB 2086) prior to treatment with oxPAPC. WEB 2086 inhibited monocyte binding to endothelial cells induced by oxPAPC (200 μg/ml) at concentrations from 1 nM to 10 μM, but had no effect on the induction of monocyte binding induced by lipopolysaccharide (LPS). We were able to isolate and identify several active oxidized phospholipids by combined normal phase high performance liquid chromatography (HPLC) and electrospray mass spectrometry (LC/MS). The induction of monocyte binding to HAECs by two of these partially purified phospholipids was totally abolished by the pretreatment of HAECs with WEB2086 (100 nM). PAF itself, however, when tested at concentrations from 10 nM to 10 μM had no effect on monocyte binding. These results suggest that several of the oxidized phospholipids present in MM-LDL and oxPAPC induce monocyte binding through a receptor which is perhaps distinct from the PAF-receptor, but can be blocked by the PAF-receptor antagonist WEB 2086.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
J.A. Berliner, M.C. Territo, A. Sevanian, S. Ramin, J.A. Kim, B. Bamshad, M. Esterson, and A.M. Fogelman, Minimally modified low density lipoprotein stimulates monocyte endothelial interactions, J. Clin. Invest. 85: 1260 (1990).
S.D. Cushing, J.A. Berliner, A.J. Valente, M.C. Territo, M. Navab, F. Parhami, R. Gerrity, C.J. Schwartz, and A.M. Fogelman AM, Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells, Proc. Natl. Acad. Sci. USA 87: 5134 (1990).
T.B. Rajavashisth, A. Andalibi, M.C. Territo, J.A. Berliner, M. Navab, A.M. Fogelman, and A.J. Lusis, Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low density lipoproteins, Nature 344: 254 (1990).
A.D. Watson, J.A. Berliner, S.Y. Hama, B.N. La Du, K.F. Faull, A.M. Fogelman, and M. Navab M, Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein, J. Clin. Invest. 96: 2882 (1995).
A.D. Watson, N. Leitinger, M. Navab, K.F. Faull, S. Hörkkö, J.L. Witztum, W. Palinski, D. Schwenke, R.G. Salomon, S. Wei, A.M. Fogelman, and J.A. Berliner, Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo, J. Biol. Chem. in press.
F. Parhami, Z.T. Fang, A.M. Fogelman, A. Andalibi, M.C. Territo, and J.A. Berliner, Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate, J. Clin. Invest. 92: 471 (1993).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Leitinger, N., Watson, A.D., Faull, K.F., Fogelman, A.M., Berliner, J.A. (1997). Monocyte Binding to Endothelial Cells Induced by Oxidized Phospholipids Present in Minimally Oxidized Low Density Lipoprotein Is Inhibited by a Platelet Activating Factor Receptor Antagonist. In: Sinzinger, H., Samuelsson, B., Vane, J.R., Paoletti, R., Ramwell, P., Wong, P.YK. (eds) Recent Advances in Prostaglandin, Thromboxane, and Leukotriene Research. Advances in Experimental Medicine and Biology, vol 433. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1810-9_82
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1810-9_82
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1812-3
Online ISBN: 978-1-4899-1810-9
eBook Packages: Springer Book Archive